PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 753.10K | 915.10K | 842.10K | 1.01M | 1.17M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 848.30K | 1.04M | 960.30K | 1.11M | 1.27M |
Operating Income | -848.30K | -1.04M | -960.30K | -1.11M | -1.27M |
Income Before Tax | -8.36M | 11.75M | -3.05M | -1.47M | 23.42M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -8.36M | 11.75M | -3.05M | -1.47M | 23.42M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -8.36M | 11.75M | -3.05M | -1.47M | 23.42M |
EBIT | -848.30K | -1.04M | -960.30K | -1.11M | -1.27M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -1.23 | 1.58 | -0.44 | -0.21 | 1.90 |
Normalized Basic EPS | -0.50 | -0.10 | 0.28 | 0.23 | 0.08 |
EPS Diluted | -1.23 | 1.58 | -0.44 | -0.21 | 1.90 |
Normalized Diluted EPS | -0.50 | -0.10 | 0.28 | 0.23 | 0.08 |
Average Basic Shares Outstanding | 6.80M | 6.85M | 6.96M | 7.64M | 7.87M |
Average Diluted Shares Outstanding | 6.80M | 6.85M | 6.96M | 7.64M | 7.87M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |